Legal Representation
Attorney
Allan Fanucci
USPTO Deadlines
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 19, 2007 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Dec 19, 2007 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| May 7, 2007 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| May 7, 2007 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| May 7, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 30, 2006 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Oct 30, 2006 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Oct 30, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 1, 2006 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 1, 2006 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 1, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 23, 2005 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 9, 2005 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 9, 2005 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 4, 2005 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 4, 2005 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 4, 2005 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 9, 2004 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 17, 2004 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 28, 2004 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Jun 4, 2004 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 27, 2004 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 27, 2004 | CNEA | F | EXAMINER'S AMENDMENT MAILED | Loading... |
| May 20, 2004 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 10, 2003 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations containing a somatostatin analog for inhibition of growth hormone secretion, or for use in treatment of gastrointestinal and endocrine disorders, cancers, pancreatitis, disorders associated with angiogenesis, autoimmune diseases and inflammatory diseases, in humans and animals
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005